276 related articles for article (PubMed ID: 15368130)
1. [Experimental investigations of the optimal therapy of systemic BCG infection in vivo].
Jurczok A; Zacharias M; Böhle A; Fornara P; Jocham D
Aktuelle Urol; 2004 Sep; 35(5):406-12. PubMed ID: 15368130
[TBL] [Abstract][Full Text] [Related]
2. Optimal treatment of systemic bacillus Calmette-Guérin infection: investigations in an animal model.
Durek C; Jurczok A; Werner H; Jocham D; Bohle A
J Urol; 2002 Aug; 168(2):826-31. PubMed ID: 12131375
[TBL] [Abstract][Full Text] [Related]
3. Effects of acetylic salicylic acid and pentoxifylline on the efficacy of intravesical BCG therapy in orthotopic murine bladder cancer (MB49).
Günther JH; Frambach M; Deinert I; Brandau S; Jocham D; Böhle A
J Urol; 1999 May; 161(5):1702-6. PubMed ID: 10210443
[TBL] [Abstract][Full Text] [Related]
4. CpG therapy is superior to BCG in an orthotopic bladder cancer model and generates CD4+ T-cell immunity.
Mangsbo SM; Ninalga C; Essand M; Loskog A; Tötterman TH
J Immunother; 2008 Jan; 31(1):34-42. PubMed ID: 18157010
[TBL] [Abstract][Full Text] [Related]
5. The fate of bacillus Calmette-Guerin after intravesical instillation.
Durek C; Richter E; Basteck A; Rüsch-Gerdes S; Gerdes J; Jocham D; Böhle A
J Urol; 2001 May; 165(5):1765-8. PubMed ID: 11342972
[TBL] [Abstract][Full Text] [Related]
6. Immunodominant PstS1 antigen of mycobacterium tuberculosis is a potent biological response modifier for the treatment of bladder cancer.
Sänger C; Busche A; Bentien G; Spallek R; Jonas F; Böhle A; Singh M; Brandau S
BMC Cancer; 2004 Nov; 4():86. PubMed ID: 15566565
[TBL] [Abstract][Full Text] [Related]
7. Optimizing syngeneic orthotopic murine bladder cancer (MB49).
Günther JH; Jurczok A; Wulf T; Brandau S; Deinert I; Jocham D; Böhle A
Cancer Res; 1999 Jun; 59(12):2834-7. PubMed ID: 10383142
[TBL] [Abstract][Full Text] [Related]
8. Intravesical Bacillus Calmette-Guérin therapy for murine bladder tumors: initiation of the response by fibronectin-mediated attachment of Bacillus Calmette-Guérin.
Ratliff TL; Palmer JO; McGarr JA; Brown EJ
Cancer Res; 1987 Apr; 47(7):1762-6. PubMed ID: 3545453
[TBL] [Abstract][Full Text] [Related]
9. Genetically regulated response to intravesical bacillus Calmette Guerin immunotherapy of orthotopic murine bladder tumor.
Kadhim SA; Chin JL; Batislam E; Karlik SJ; Garcia B; Skamene E
J Urol; 1997 Aug; 158(2):646-52. PubMed ID: 9224385
[TBL] [Abstract][Full Text] [Related]
10. [Intravesical adjuvant chemotherapy for superficial bladder cancer -- results of a survey in Saxony].
Steinbach F; Schuster F
Aktuelle Urol; 2005 Aug; 36(4):337-41. PubMed ID: 16110407
[TBL] [Abstract][Full Text] [Related]
11. [Effect of prophylactic intravesical instillation of BCG for superficial bladder cancer].
Segawa N; Inamoto T; Nomi H; Ibuki N; Azuma H; Katsuoka Y
Hinyokika Kiyo; 2009 Apr; 55(4):175-80. PubMed ID: 19462820
[TBL] [Abstract][Full Text] [Related]
12. Impaired immune response by isoniazid treatment during intravesical BCG administration in the guinea pig.
de Boer EC; Steerenberg PA; van der Meijden AP; van Klingeren B; de Jong WH; Debruyne FM; Ruitenberg EJ
Prog Clin Biol Res; 1992; 378():81-93. PubMed ID: 1301589
[TBL] [Abstract][Full Text] [Related]
13. [Novel vaccines against M. tuberculosis].
Okada M
Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920
[TBL] [Abstract][Full Text] [Related]
14. Reduction of bladder tumor growth in mice treated with intravesical Bacillus Calmette-Guérin and its correlation with Bacillus Calmette-Guérin viability and natural killer cell activity.
Shapiro A; Ratliff TL; Oakley DM; Catalona WJ
Cancer Res; 1983 Apr; 43(4):1611-5. PubMed ID: 6339040
[TBL] [Abstract][Full Text] [Related]
15. In vitro and in vivo effects of CpG-Oligodeoxynucleotides (CpG-ODN) on murine transitional cell carcinoma and on the native murine urinary bladder wall.
Olbert PJ; Schrader AJ; Simon C; Dalpke A; Barth P; Hofmann R; Hegele A
Anticancer Res; 2009 Jun; 29(6):2067-76. PubMed ID: 19528466
[TBL] [Abstract][Full Text] [Related]
16. BCG-related granulomatous hepatitis.
Hristea A; Neacsu A; Ion DA; Streinu-Cercel A; Stăniceanu F
Pneumologia; 2007; 56(1):32-4. PubMed ID: 17491206
[TBL] [Abstract][Full Text] [Related]
17. Treatment of bladder carcinomas using recombinant BCG DNA vaccines and electroporative gene immunotherapy.
Lee CF; Chang SY; Hsieh DS; Yu DS
Cancer Gene Ther; 2004 Mar; 11(3):194-207. PubMed ID: 14973549
[TBL] [Abstract][Full Text] [Related]
18. Preexisting BCG-specific T cells improve intravesical immunotherapy for bladder cancer.
Biot C; Rentsch CA; Gsponer JR; Birkhäuser FD; Jusforgues-Saklani H; Lemaître F; Auriau C; Bachmann A; Bousso P; Demangel C; Peduto L; Thalmann GN; Albert ML
Sci Transl Med; 2012 Jun; 4(137):137ra72. PubMed ID: 22674550
[TBL] [Abstract][Full Text] [Related]
19. Role of animal models in understanding intravesical therapy with bacille Calmette-Guérin.
Ratliff TL
Clin Infect Dis; 2000 Sep; 31 Suppl 3():S106-8. PubMed ID: 11010834
[TBL] [Abstract][Full Text] [Related]
20. Intravesical instillation therapy with bacillus Calmette-Guérin for superficial bladder cancer: study of the mechanism of bacillus Calmette-Guérin immunotherapy.
Shintani Y; Sawada Y; Inagaki T; Kohjimoto Y; Uekado Y; Shinka T
Int J Urol; 2007 Feb; 14(2):140-6. PubMed ID: 17302571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
